07:00:22 EDT Thu 13 Aug 2020
Enter Symbol
or Name

Login ID:
Stagezero Life Sciences Ltd
Symbol SZLS
Shares Issued 227,232,793
Close 2019-08-09 C$ 0.115
Recent Sedar Documents

Stagezero Life to release Q2 2019 results Aug. 14

2019-08-12 09:46 ET - News Release

Mr. James Howard-Tripp reports


Stagezero Life Sciences Ltd. will release its second quarter 2019 operational results before market open on Wednesday, Aug. 14, 2019. Stagezero's chairman and chief executive officer, James R. Howard-Tripp, will host a conference call at 8:30 a.m. ET on Aug. 14, 2019, to review the operational results and discuss business developments for the period.

Date:  Wednesday, Aug. 14, 2019

Participant dial-in:  844-602-0380

International dial-in:  862-298-0970

Replay number:  877-481-4010

International replay:  919-882-2331

Replay code:  53250

Teleconference replay expiration:  Aug. 21, 2019

About Stagezero Life Sciences Ltd.

Stagezero Life is dedicated to the early detection of cancer and multiple disease states through whole blood. Its next-generation test, Aristotle, is a multicancer panel for simultaneously screening for 10 cancers from a single sample of blood, with high sensitivity and specificity for each cancer. Aristotle is built on the company's proven and proprietary Sentinel Principle technology platform, which was validated on 10,000 patients and used to develop the first liquid biopsy for colorectal cancer.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.